Takeda Pharmaceutical Company Ltd

HYQVIA, the first facilitated subcutaneous immunoglobulin therapy, approved in Japan for agammaglobulinemia and hypogammaglobulinemia, offers reduced dosing frequency and increased administration flexibility.

Puma Biotechnology's stock rose 24% due to Nerlynx's sales, expected to reach $187-$190M in 2024. The company is developing alisertib for cancer, with phase II studies underway, aiming to diversify beyond Nerlynx.

Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, in San Francisco, discussing the company's global innovation strategy.

The global Myelodysplastic Syndrome (MDS) Drugs market is projected to grow from US$2.2B in 2023 to US$4.1B by 2030, driven by increasing incidence rates, advancements in treatment, and strategic collaborations. Immunomodulatory Drugs are expected to dominate, reaching US$2.7B by 2030. North America leads, with China forecasted to grow at 13.7% CAGR.

Bristol Myers Squibb announced positive Phase III results for Sotyktu (deucravacitinib) in psoriatic arthritis, showing greater treatment response compared to placebo. Sotyktu, an oral TYK2 inhibitor, is approved for plaque psoriasis and saw $170m in sales in 2023, projected to rise to $2.2bn by 2030.

Ethics in the pharmaceutical industry is crucial for public trust and patient care. The article highlights the importance of hiring people with values, focusing on patient care, rewarding ethical behavior, fostering mentorship, and creating an ecosystem of ethics. It emphasizes the need for accountability and integrity in decision-making to prevent reputational damage and ensure the industry thrives on trust.

In 2024, India's CDSCO approved 19 new drugs, including next-gen therapies for chronic diseases by global majors. Eli Lilly's Mounjaro for diabetes/obesity, Orchid Pharma's Enmetazobactam for resistant bacteria, Cipla's plazomicin for UTIs, Sun Pharma's Etifoxine for anxiety, Dr Reddy's Elobixibat for constipation, and Zydus/Lupin's Vonoprazan for stomach ulcers were notable. New cancer drugs like Eli Lilly's Retevmo and Zydus's nelarabine were also approved.

GSK's linerixibat, an IBAT inhibitor, shows promise for PBC-related itch, achieving significant itch reduction in Phase III. Novartis' TAK-756 targets OA with minimal systemic exposure. Enterprise's ETD001, an ENaC inhibitor, advances in CF treatment. Aligos' ALG-000184 reduces HBV markers, offering CHB treatment potential. Roche's compound 39 improves NLRP3 inhibition. Servier's compound 23 targets KEAP1/Nrf2 axis. Accent's ATX968 inhibits DHX9, targeting MSI-H/dMMR cancers. Gilead's GS-2278, an LPAR1 antagonist, discontinued for IPF due to CNS toxicity. Insilico's compound 13 shows promise in CDK7 inhibition with reduced toxicity. Alisertib, an AURKA inhibitor, explored in cancer trials, shows potential in reversing immunotherapy resistance.

Merck licenses a GLP-1 candidate from Hansoh Pharma; Astellas collaborates with Sangamo for gene therapy; Betta Pharma's Ensacove gains FDA approval for lung cancer; Mitsubishi Tanabe attracts buyout interest; BeiGene licenses a MAT2A inhibitor; Candid Therapeutics forms new collaborations; BMS regains China rights to a RayzeBio candidate.

Roche and Prothena's prasinezumab, targeting alpha-synuclein for Parkinson's, missed primary endpoint in phase 2b PADOVA trial but showed numerical delay in motor progression and positive trends on secondary endpoints. Roche plans further exploration and collaboration with Parkinson's community.